TIDMCLIN
RNS Number : 6807G
Clinigen Group plc
26 November 2020
26 November 2020
Result of AGM and Resignation of Non-Executive Director
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the
global pharmaceutical and services company, held its Annual General
Meeting ('AGM') today at which all resolutions were passed.
Resolutions 1-15 were passed as Ordinary Resolutions and
Resolutions 14 and 15 were passed as Special Resolutions.
As previously announced in September 2020, John Hartup the
Senior Independent Non-Executive Director, decided not to stand for
re-election at the AGM and therefore, he has resigned as a Director
of the Company with effect from today, 26 November. Consequently,
Anne Hyland has been appointed as the Senior Independent Director
and Alan Boyd has been appointed to engage with the workforce on
behalf of the board as the designated Non-Executive Director. Both
of these appointments are effective from 26 November 2020. The
Nomination Committee has also started the search process for a new
independent Non-Executive Director.
The voting results at the AGM are given in the table below.
For Against Discretionary
/ Withheld
Resolution Number % Number % Number
------------ -------- ---------- ------ ----------------
1. To receive the audited financial
statements and the Auditors' and
Directors' Reports for the year
ended 30 June 2020. 94,363,546 100.00% 285 0.00% 89,188
------------ -------- ---------- ------ ----------------
2. To approve the Directors' Remuneration
Report (other than the part containing
the Directors' remuneration policy)
for the year ended 30 June 2020. 89,044,191 94.28% 5,404,286 5.72% 4,542
------------ -------- ---------- ------ ----------------
3. To declare a final dividend
of 5.46p per share for the year
ended 30 June 2020. 94,451,582 100.00% 285 0.00% 1,152
------------ -------- ---------- ------ ----------------
4. To re-elect Peter Allen as
a Director. 82,526,572 87.38% 11,918,235 12.62% 8,212
------------ -------- ---------- ------ ----------------
5. To re-elect Ian Nicholson as
a Director. 92,566,213 98.02% 1,866,630 1.98% 20,176
------------ -------- ---------- ------ ----------------
6. To re - elect Anne Hyland as
a Director. 93,911,041 99.45% 521,802 0.55% 20,176
------------ -------- ---------- ------ ----------------
7. To re - elect Alan Boyd as
a Director. 79,091,727 83.93% 15,138,298 16.07% 222,994
------------ -------- ---------- ------ ----------------
8. To re - elect Shaun Chilton
as a Director. 93,543,054 99.04% 906,789 0.96% 3,176
------------ -------- ---------- ------ ----------------
9. To re-elect Nick Keher as a
Director. 93,258,324 98.74% 1,191,674 1.26% 3,021
------------ -------- ---------- ------ ----------------
10. To reappoint PricewaterhouseCoopers
LLP
as auditors. 91,007,732 96.36% 3,438,680 3.64% 6,607
11. To authorise the Directors
to determine the auditors' remuneration. 91,800,589 97.20% 2,640,554 2.80% 11,876
------------ -------- ---------- ------ ----------------
12. To grant the Company authority
to make political donations. 80,071,917 91.21% 7,715,738 8.79% 6,665,364
------------ -------- ---------- ------ ----------------
13. To authorise the Directors
to allot shares pursuant to section
551 of the Companies Act 2006. 93,845,132 99.36% 601,552 0.64% 6,335
14. To empower the Directors to
disapply pre-emption rights. 89,624,066 94.90% 4,820,119 5.10% 8,834
------------ -------- ---------- ------ ----------------
15. To empower the Directors to
disapply pre-emption rights in
relation to shares issued in connection
with an acquisition or specified
capital investment. 88,456,906 93.66% 5,986,979 6.34% 9,134
------------ -------- ---------- ------ ----------------
Note: As at 26 November 2020, Clinigen has 133,028,647 ordinary
shares of 0.1 pence each in issue and the total number of voting
rights is 133,028,647 .
- Ends -
For further information, please contact:
Clinigen Group plc Tel: +44 (0) 1283 495
010
Shaun Chilton, Group Chief Executive Officer
Nick Keher, Group Chief Financial Officer
J.P.Morgan Cazenove - Nominated Adviser & Tel: +44 (0)20 7742
Joint Broker 4000
James Mitford / Hemant Kapoor
RBC Capital Markets - Joint Broker Tel: +44 (0)20 7653
4000
Marcus Jackson / Elliot Thomas
Instinctif Partners Tel: +44 (0)20 7457
2020
Melanie Toyne Sewell / Phillip Marriage Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing ethical access to medicines. Its mission is to deliver
the right medicine to the right patient at the right time through
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines. The Group has sites in North America,
Europe, Africa and the Asia Pacific region.
Clinigen now has over 1,150 employees across five continents in
14 countries, with supply and distribution hubs and operational
centres of excellence in key long term growth regions. The Group
works with 21 of the top 25 pharmaceutical companies; interacting
with over 18,000 registered users across 115 countries, shipping
approximately 6.5 million units in the year.
For more information on Clinigen, please visit
www.clinigengroup.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGFLFFRLDLRFII
(END) Dow Jones Newswires
November 26, 2020 11:28 ET (16:28 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024